[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
October 28, 2013

Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety

Author Affiliations
  • 1Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey
JAMA Intern Med. 2013;173(19):1842-1843. doi:10.1001/jamainternmed.2013.8138

To the Editor We would like to highlight important methodological limitations to the case-control study by Singh et al,1 in which the authors investigated whether an association might exist between acute pancreatitis and use of glucagon-like peptide 1 (GLP-1)–based therapies in patients with type 2 diabetes mellitus using an insurance claims database.

First Page Preview View Large
First page PDF preview
First page PDF preview
×